HRP20192278T1 - Derivati 8-hidroksi-kinolina - Google Patents
Derivati 8-hidroksi-kinolina Download PDFInfo
- Publication number
- HRP20192278T1 HRP20192278T1 HRP20192278TT HRP20192278T HRP20192278T1 HR P20192278 T1 HRP20192278 T1 HR P20192278T1 HR P20192278T T HRP20192278T T HR P20192278TT HR P20192278 T HRP20192278 T HR P20192278T HR P20192278 T1 HRP20192278 T1 HR P20192278T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- groups
- branched
- carbon atoms
- lower alkyl
- Prior art date
Links
- 150000004325 8-hydroxyquinolines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Claims (1)
1. Spojevi prema općoj formuli (I)
naznačeni time, da
R1 predstavlja atom vodika, nižu alkilnu skupinu, koja je razgranana ili nerazgranana alkilna skupina s 1 do 4 atoma ugljika, nižu alkenilnu skupinu, koja je razgranana ili nerazgranana alkenilna skupina s 2 do 4 atoma ugljika, arilnu skupinu, aralkilnu skupinu ili heterocikličku skupinu, pri čemu su gore navedene arilne, aralkilne i heterocikličke skupine opcionalno supstituirane u orto, meta i / ili para položaju s 1, 2, 3 ili 4 skupine koje povlače elektrone, odabrane između atoma halogena, trifluorometila ili nitro skupina ili skupina koje doniraju elektrone odabrane iz nižih alkilnih skupina, koje su razgranane ili nerazgranane alkilne skupine s 1 do 4 atoma ugljika;
R2 predstavlja atom vodika, nižu alkilnu skupinu, koja je razgranana ili nerazgranana alkilna skupina s 1 do 4 atoma ugljika, arilnu skupinu, aralkilnu skupinu ili heterocikličku skupinu, pri čemu su gornje skupine po izboru supstituirane s jednim ili više atoma halogena;
R3 predstavlja arilnu skupinu, aralkilnu skupinu ili heterocikličku skupinu, pri čemu su gornje skupine izborno supstituirane u orto, meta ili para položaju s 1, 2, 3 ili 4 skupine koje povlače elektrone odabrane između atoma halogena, trifluorometil ili nitro skupina ili skupina koje doniraju elektrone odabrane iz nižih alkilnih skupina, koje su razgranane ili nerazgranane alkilne skupine s 1 do 4 atoma ugljika;
R4 predstavlja atom vodika, nižu alkilnu skupinu, koja je razgranana ili nerazgranana alkilna skupina s 1 do 4 atoma ugljika, ili kiselu funkcionalnu skupinu odabranu iz metoksikarbonilne skupine, nitrilne ili kiselinske amidne skupine;
n je 1 ili 2;
i njihova farmaceutski prihvatljiva sol za upotrebu u postupku za profilaksu ili liječenje ishemije, reperfuzijske ozljede, kardiovaskularnih poremećaja, neurodegenerativnih poremećaja (uključujući osobito Alzheimerovu i Huntingtonovu bolest), traume, neuropsihijatrijske bolesti (uključujući osobito depresiju i anksiozni poremećaji) te ozljede jetre, bubrega i pluća.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1000243A HUP1000243A2 (en) | 2010-05-06 | 2010-05-06 | 8-hidroxy-quinoline derivatives |
| PCT/HU2011/000043 WO2011148208A1 (en) | 2010-05-06 | 2011-05-06 | 8-hydroxy-quinoline derivatives |
| EP11752335.7A EP2566849B1 (en) | 2010-05-06 | 2011-05-06 | 8-hydroxy-quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192278T1 true HRP20192278T1 (hr) | 2020-03-06 |
Family
ID=89989711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192278TT HRP20192278T1 (hr) | 2010-05-06 | 2019-12-18 | Derivati 8-hidroksi-kinolina |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8871937B2 (hr) |
| EP (1) | EP2566849B1 (hr) |
| JP (1) | JP5812541B2 (hr) |
| KR (1) | KR101837974B1 (hr) |
| CN (1) | CN102985407B (hr) |
| AU (1) | AU2011256989B2 (hr) |
| CA (1) | CA2798419C (hr) |
| CY (1) | CY1122426T1 (hr) |
| DK (1) | DK2566849T3 (hr) |
| EA (1) | EA021026B1 (hr) |
| ES (1) | ES2761832T3 (hr) |
| HR (1) | HRP20192278T1 (hr) |
| HU (2) | HUP1000243A2 (hr) |
| MX (1) | MX337999B (hr) |
| NZ (1) | NZ603967A (hr) |
| PL (1) | PL2566849T3 (hr) |
| PT (1) | PT2566849T (hr) |
| RS (1) | RS59678B1 (hr) |
| SI (1) | SI2566849T1 (hr) |
| WO (1) | WO2011148208A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP1500098A2 (hu) * | 2015-03-09 | 2016-09-28 | Avidin Kft | 8-hidroxikinolin származékok új enantiomerjei és szintézisük |
| US10624881B2 (en) * | 2015-10-12 | 2020-04-21 | Health Research, Inc. | Methods for inducing apoptosis in cancer cells |
| CN105367553A (zh) * | 2015-12-04 | 2016-03-02 | 广东工业大学 | 一种他克林-8-羟（胺）基喹啉衍生物及其应用 |
| HUP1600234A2 (en) | 2016-04-05 | 2017-12-28 | Mta Termeszettudomanyi Kutatokoezpont | Mdr-reversing 8-hydroxy-quinoline derivatives |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999015179A1 (en) | 1997-09-25 | 1999-04-01 | Regents Of The University Of Minnesota | Methods of limiting apoptosis of cells |
| US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| AU2474399A (en) | 1998-01-26 | 1999-08-09 | Mitokor | Mitochondria protecting agents for treating mitochondria associated diseases |
| US6737511B1 (en) | 1999-08-16 | 2004-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis |
| US6495522B1 (en) | 1999-08-27 | 2002-12-17 | Cytovia, Inc. | Substituted alpha-hydroxy acid caspase inhibitors and the use thereof |
| US6890896B1 (en) | 1999-11-18 | 2005-05-10 | Ceremedix, Inc. | Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
| US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
| GB0011095D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | astrin and cholecystokinin receptor ligands (III) |
| US6521617B2 (en) | 2000-10-13 | 2003-02-18 | The Johns Hopkins University | Treatment of apoptotic cell death |
| US6552076B2 (en) | 2000-12-15 | 2003-04-22 | Mitokor | Compounds for altering mitochondrial function and cellular responses |
| US7601846B2 (en) | 2001-06-26 | 2009-10-13 | The Regents Of The University Of California | Compounds having activity as inhibitors of apoptosis |
| CA2452005C (en) | 2001-07-10 | 2011-03-15 | Idec Pharmaceutical Corporation | Inhibition of apoptosis process and improvement of cell performance |
| DE10144153A1 (de) | 2001-09-07 | 2003-03-27 | Newfrey Llc | Halteclip mit versetzten Rastfingern |
| JP2005525848A (ja) | 2002-02-13 | 2005-09-02 | ベス イスラエル ディコネス メディカル センター | 血管疾患の治療方法 |
| WO2005009398A2 (en) | 2003-02-28 | 2005-02-03 | Inotek Pharmaceuticals Corporation | Tetracyclic benzamide derivatives and methods of use thereof |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| AU2004242947B2 (en) | 2003-05-28 | 2010-04-29 | Eisai Inc. | Compounds, methods and pharmaceutical compositions for inhibiting PARP |
| CA2971928C (en) | 2004-01-23 | 2019-01-08 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| ES2342007T3 (es) | 2005-11-15 | 2010-06-30 | Abbott Laboratories | 1h-benzimidazol-4-carboxamidas sustituidos eficaces como inhibidores de (parp). |
| US7528174B2 (en) | 2006-01-06 | 2009-05-05 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Selective targeting agents for mitochondria |
| AU2007280984A1 (en) * | 2006-07-25 | 2008-02-07 | Envivo Pharmaceutical Inc. | Quinoline derivatives |
| EP3085367A3 (en) * | 2007-03-20 | 2017-01-25 | Brandeis University | Compositions for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related |
| US8183236B2 (en) * | 2007-04-12 | 2012-05-22 | University Of Southern California | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics |
| EP2148944A1 (en) | 2007-05-25 | 2010-02-03 | Burnham Institute for Medical Research | Inhibitors of thapsigargin-induced cell death |
| US8138356B2 (en) * | 2007-10-16 | 2012-03-20 | Angiogeney, Inc. | Chemical inhibitors of inhibitors of differentiation |
| WO2009151972A1 (en) * | 2008-05-28 | 2009-12-17 | , The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Materiel Command | Small molecule inhibitors of botulinum neurotoxins |
| US8618302B2 (en) * | 2010-01-06 | 2013-12-31 | Joseph P. Errico | Methods and compositions of targeted drug development |
| US8658170B2 (en) * | 2010-01-06 | 2014-02-25 | Joseph P. Errico | Combination therapy with MDM2 and EFGR inhibitors |
-
2010
- 2010-05-06 HU HU1000243A patent/HUP1000243A2/hu unknown
-
2011
- 2011-05-06 SI SI201131826T patent/SI2566849T1/sl unknown
- 2011-05-06 PL PL11752335T patent/PL2566849T3/pl unknown
- 2011-05-06 CN CN201180033524.5A patent/CN102985407B/zh active Active
- 2011-05-06 US US13/696,541 patent/US8871937B2/en active Active
- 2011-05-06 AU AU2011256989A patent/AU2011256989B2/en active Active
- 2011-05-06 NZ NZ603967A patent/NZ603967A/en unknown
- 2011-05-06 KR KR1020127030702A patent/KR101837974B1/ko active IP Right Grant
- 2011-05-06 MX MX2012012883A patent/MX337999B/es active IP Right Grant
- 2011-05-06 ES ES11752335T patent/ES2761832T3/es active Active
- 2011-05-06 HU HUE11752335A patent/HUE050886T2/hu unknown
- 2011-05-06 EA EA201270787A patent/EA021026B1/ru unknown
- 2011-05-06 PT PT117523357T patent/PT2566849T/pt unknown
- 2011-05-06 EP EP11752335.7A patent/EP2566849B1/en active Active
- 2011-05-06 CA CA2798419A patent/CA2798419C/en active Active
- 2011-05-06 JP JP2013508559A patent/JP5812541B2/ja active Active
- 2011-05-06 RS RS20191622A patent/RS59678B1/sr unknown
- 2011-05-06 DK DK11752335.7T patent/DK2566849T3/da active
- 2011-05-06 WO PCT/HU2011/000043 patent/WO2011148208A1/en active Application Filing
-
2019
- 2019-12-17 CY CY20191101327T patent/CY1122426T1/el unknown
- 2019-12-18 HR HRP20192278TT patent/HRP20192278T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201270787A1 (ru) | 2013-04-30 |
| KR20130029772A (ko) | 2013-03-25 |
| JP5812541B2 (ja) | 2015-11-17 |
| US8871937B2 (en) | 2014-10-28 |
| HUP1000243A2 (en) | 2012-01-30 |
| CA2798419C (en) | 2021-01-05 |
| ES2761832T3 (es) | 2020-05-21 |
| MX2012012883A (es) | 2013-03-20 |
| US20130131096A1 (en) | 2013-05-23 |
| JP2013525473A (ja) | 2013-06-20 |
| CY1122426T1 (el) | 2021-01-27 |
| CN102985407B (zh) | 2015-09-09 |
| EP2566849B1 (en) | 2019-09-18 |
| HUE050886T2 (hu) | 2021-01-28 |
| NZ603967A (en) | 2014-06-27 |
| AU2011256989B2 (en) | 2014-08-21 |
| AU2011256989A1 (en) | 2013-01-10 |
| HU1000243D0 (en) | 2010-06-28 |
| CA2798419A1 (en) | 2011-12-01 |
| CN102985407A (zh) | 2013-03-20 |
| PL2566849T3 (pl) | 2020-03-31 |
| EA021026B1 (ru) | 2015-03-31 |
| PT2566849T (pt) | 2020-01-06 |
| KR101837974B1 (ko) | 2018-03-13 |
| MX337999B (es) | 2016-03-30 |
| SI2566849T1 (sl) | 2020-02-28 |
| EP2566849A1 (en) | 2013-03-13 |
| WO2011148208A1 (en) | 2011-12-01 |
| RS59678B1 (sr) | 2020-01-31 |
| DK2566849T3 (da) | 2020-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192278T1 (hr) | Derivati 8-hidroksi-kinolina | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| BR112015004529A2 (pt) | alcóxi pirazóis como ativadores de guanilato ciclase solúvel | |
| AR125150A2 (es) | Sulfóxidos de piperidino-dihidrotienopirimidina y su uso para tratar epoc y asma | |
| BR112015009395A2 (pt) | processo para preparação de derivados do ácido biliar | |
| HRP20210775T1 (hr) | Predlijekovi fenolnih agonista trpv1 | |
| IN2014MN01839A (hr) | ||
| BR112017000943A2 (pt) | ácidos carboxílicos heterocíclicos como ativadores de guanilato ciclase solúveis | |
| MX2014015501A (es) | Carboxamidas heterociclicas fungicidas. | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| TN2015000102A1 (en) | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors | |
| MY172924A (en) | Neprilysin inhibitors | |
| BR112014030743A2 (pt) | inibidores de neprilisina | |
| AR091857A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| BR112012027385A2 (pt) | composição para o controle de doenças de plantas e uso da mesma | |
| ME01595B (me) | Benzamidinska jedinjenja koja su korisna kao inhibitori histonske deacetilaze | |
| HRP20171041T1 (hr) | Nova sol abeksinostata, s njome povezani kristalni oblik, postupak pripreme i farmaceutske tvari koje ih sadrže | |
| JP2016529319A5 (hr) | ||
| EA201792597A3 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| BR112013021941A2 (pt) | agente terapêutico para tumor | |
| EA201492255A1 (ru) | Феноксиэтилпиперидиновые соединения | |
| BR112015029504A2 (pt) | inibidores quinase | |
| RS54539B1 (en) | USE OF 1H-INDASOL-3-CARBOXAMIDE COMPOUNDS AS A 3-BETA GLYCOGEN SYNTHETASE KINASE INHIBITOR | |
| FR2970000B1 (fr) | Nouveau procede de synthese de l'agomelatine | |
| HRP20070518T5 (hr) | DERIVATI 4-OKSO-4,6,7,8-TETRAHIDROPIROLO-1,2-a PIRAZIN-6-KARBOKSAMIDA, POSTUPAK NJIHOVE PRIPRAVE I NJIHOVE FARMACEUTSKE SMJESE |